Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficacy of nimesulide (100mg twice daily) was compared with that of naproxen (500mg twice daily) in 53 adult patients with nonbacterial acute inflammation of the ear, nose or throat in a double-blind phase III clinical investigation. Both drugs were administered orally after meals for a mean duration of 8.7 days. In this setting, nimesulide was associated with relief of pain and inflammatory signs (exudation and swelling). Indeed, treatment with nimesulide led to clinical improvement superior to that obtained with naproxen in terms of both rapidity of action and improvement of the symptoms at the end of therapy. Nimesulide therapy was also very well tolerated and no patient reported an adverse event. In contrast, 2 naproxen-treated patients reported episodic gastralgia of moderate intensity.
 ...
PMID:Nimesulide granules for the treatment of acute inflammation of the ear, nose or throat. 750 45

In a randomised double-blind study, nimesulide 100mg twice daily for 8 days was compared with placebo in the treatment of 60 patients with ankle sprain. On day 4, three nimesulide-treated patients discontinued treatment because of resolution of their symptoms, whereas 11 patients in the placebo group discontinued as a result of worsening symptoms. A significantly greater reduction in pain, functional impairment and swelling was observed with nimesulide compared with placebo; moreover, the time to improvement was significantly shorter with the active treatment. The overall evaluation of efficacy favoured nimesulide over placebo (p < 0.001). Both medications were well tolerated, with 5 patients reporting mild gastralgia (4 treated with nimesulide and 1 with placebo), while 1 placebo-treated patient reported a mild gastrointestinal disturbance. These results suggest that nimesulide is an effective treatment for the short term management of post-traumatic pain states.
 ...
PMID:A double-blind study of the efficacy of nimesulide in the treatment of ankle sprain in comparison with placebo. 750 67

The efficacy and safety of ipriflavone, a new anti-osteoporotic agent, has been evaluated in an open study in 100 agent, has been evaluated in an open study in 100 osteoporotic women. Ipriflavone was administered as oral capsules dosed at 200 mg, 3 times a day for 12 months. Ninety women completed the study, and the results indicate that the bone mineral density was increased by 2% and 5.8% after 6 and 12 months, respectively. Pain and rachis mobility seemed to be positively influenced by ipriflavone. Only three women complained of side-effects (gastralgia and nausea) and asked to stop the therapy.
 ...
PMID:New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone. 784 6

Results from a prospective cohort of 136 children, from 4 to 10 years of age, indicated that stomach ache was almost as prevalent among preschool children as children of school age. Headache was almost absent among 4-year-olds but prevalent at 10 years of age. Generally, early pain complaints were persistent. The co-occurrence of stomach ache and headache increased from 4% of children at 4 years of age to 20% when they reached 10 years of age.
 ...
PMID:Prevalence and persistence of stomach ache and headache among children. Follow-up of a cohort of Norwegian children from 4 to 10 years of age. 802 5

The relationship between gastrointestinal (GI) symptoms and uterine cramping pain at menses, controlling for affective states and prostaglandin synthesis inhibitor use, was examined. A total of 53 women completed a daily diary of symptoms, stool characteristics, and medication use for three consecutive menstrual cycles. There were significant across-women and within-woman relationships between stomach pain, nausea, and uterine cramping pain, but not between cramping pain and constipation, diarrhea, or stool characteristics. These results support the presence of a similar mechanism in the generation of distressing GI symptoms and uterine cramping pain at menses.
 ...
PMID:Relationship between gastrointestinal and dysmenorrheic symptoms at menses. 855 2

The shame response is a primitive physiological response to a rejection of oneself by another. The discomfort of this response may vary from intense physical pain to one that is barely noticeable, if at all. When this pain is sufficient, it causes anger that may be directed outward against another or inward against oneself. The intensity of the shame response, hence the intensity of the pain and anger, is related to the significance of the other, the significance of witnesses to the rejection, one's vulnerability, whether or not the rejection is of oneself or an aspect of oneself, and if the rejection comes as a surprise. When most intense (i.e., most painful), the shame response may include a tightness of the throat, nausea, stomach pain, and a sense that the contents of one's chest and abdomen are collapsing, exploding, or imploding. In reviewing what preceded an act of violence, it is necessary to determine whether the assailant had experienced a shame response and how intense it was. Understanding that a shame response can lead to anger and violence allows for the prevention of violence. This requires that individuals do not experience rejections that are so painful as to lead to violence.
 ...
PMID:Experiencing a shame response as a precursor to violence. 863 86

There is some evidence that nabumetone (1000 mg once daily) in comparison with piroxicam (20 mg once daily) in patients with OA in general practice is associated with a lower incidence and less severe occurrence of stomach pain but with more withdrawals due to lack of efficacy. The aim of this analysis was to investigate whether these differences are reflected in health-related quality of life assessments. Patients (n = 198) included in this study were selected in general practice according to a protocol. The patients were randomized and treated for a period of six weeks. Clinical assessments were performed by the general practitioner (CP) during treatment. The Sickness Impact Profile (SIP), the Activities of Daily Living (ADL), and a pain questionnaire were filled out by the patients before and after treatment. As measured with the SIP, the ADL and the pain questionnaire, there were no significant differences between nabumetone and piroxicam. The correlations between (changes in) patient assessments and (changes in) clinical assessments were low. The differences between the two drugs regarding withdrawals and adverse events were not reflected by patient health-related quality of life assessments. There was a low correlation between patient health-related quality of life assessment and clinical assessments. To get a complete picture of the efficacy and safety of a drug, patient health-related quality of life assessments should be a part of a clinical trial.
 ...
PMID:Health-related quality of life assessments in osteoarthritis during NSAID treatment. 887 28

During the last two decades, there has been a trend to use low-dose I-131 ablation therapy in patients with thyroid carcinoma without metastases. However, information regarding the incidence of acute adverse reactions in patients after low-dose radioiodine therapy has not been reported. In this study, the acute radiation effects after low-dose radioiodine ablation therapy in postsurgical differentiated thyroid cancer patients was evaluated. Fifty-six patients with differentiated thyroid cancer were prospectively evaluated. None of these patients had evidence of a distant metastasis. All patients received 40 mCi (1480 MBq) I-131 MIBG orally and were evaluated for symptoms and signs by a physician on the second and seventh days after therapy. Xerostomia and nausea were the most common complaints with the same incidence rate of 5.35%. Gastralgia occurred at a frequency of 3.57%. Pain in the thyroid bed, tenderness over a parotid gland, submandibular glands, change in taste, and vomiting all were found at a frequency of 1.78%. Maximum reactions generally occurred 24-48 hours after therapy. All the symptoms except for xerostomia resolved completely in most patients within a week. In comparison with high-dose ablation therapy published in the literature, the incidence of radiation reactions in low-dose radioiodine therapy was much lower. It was concluded that in patients without lymph node or distant metastases, low-dose I-131 MIBG therapy may be recommended to avoid the high incidence of local complications after high-dose treatment.
 ...
PMID:Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. 889 26

Between 1983 and 1988 we treated 36 patients with sporadic amyotrophic lateral sclerosis (ALS) by an array of antioxidants and added other drugs to the regimen whenever a patient reported deterioration. Our customary prescription sequence was N-acetylcysteine (NAC); vitamins C and E; N-acetylmethionine (NAM); and dithiothreitol (DTT) or its isomer dithioerythritol (DTE). Patients with a history of heavy exposure to metal were also given meso 2,3-dimercaptosuccinic acid (DMSA). NAC, NAM, DTT, and DTE were administered by subcutaneous injection or by mouth or by both routes, the other vitamins and DMSA by mouth alone. The hospital pharmacy supplied NAC and NAM injections fluid as 100 ml bottles of 5.0 and 5.85% solutions, respectively. DTT was delivered in special double-walled capsules of 200 mg. DTT/DTE injection fluid was added to the NAC and NAM bottles, the final DTT/DTE concentrations never exceeding 0.5%. DMSA was provided in 250 mg capsules. All of the 36 patients used NAC and DTT/DTE; 29 also used vitamins C and E; 21 also used NAM; and 7 also used DMSA, DMSA, NAM, vitamins C and E were tolerated well. In many patients, DTT, DTE, NAC and NAM induced pain, redness and swelling at the injection sites in that order of decreasing frequency. DTT and DTE did often and NAC did sometimes cause gastric pain, nausea and other abdominal discomfort. Comparison of survival in the treated group and in a cohort of untreated historical controls, disclosed a median survival of 3.4 years (95% confidence interval: 3.0-4.2) in the treated and of 2.8 (95% confidence interval 2.2-3.1) years in the control patients. This difference may be explained by self-selection of our highly motivated treated group and by its initial survival of diagnosis for an average of 8.5 months before onset of treatment. We conclude that antioxidants neither seem to harm ALS patients, nor do they seem to prolong survival.
 ...
PMID:Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. 889 67

The major purpose of this study was to determine if 31 patients with fibromyalgia syndrome (FS) reported different pain intensity and Health Locus of Control (HLC) scores than 30 patients with rheumatoid arthritis (RA). Another purpose was to determine the relationship among experienced actual pain (present, usual, worse, least), recalled prior episodes of pain (worse toothache, headache, and stomach ache), HLC orientation, age and the duration of the actual pain. Visual Analogue Scales were used to measure pain intensity. The Health Locus of Control Scale was used to determine external/internal orientation. The results showed that the FS patients reported significantly more intense actual pain, recalled pain for worse toothache and headache, and were more externally oriented than the RA patients. Present pain intensity was significantly correlated to actual intensity ratings, but not to reported earlier experienced pain, except for worse stomach ache in the RA group. The findings' implications for treatment and education are discussed.
 ...
PMID:Pain intensity and health locus of control: a comparison of patients with fibromyalgia syndrome and rheumatoid arthritis. 900 34


<< Previous 1 2 3 4 5 6 7 8 Next >>